Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3630598 | 0.96 | FFAR1 (0.37) | FFAR1MAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL3631549 | 0.93 | FFAR1 (0.45) | FFAR1MAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL3624456 | 0.93 | FFAR1 (0.34) | FFAR1MAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL3631691 | 0.90 | FFAR1 (0.43) | FFAR1MAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL3631548 | 0.89 | FFAR1 (0.40) | FFAR1MAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL3631606 | 0.89 | FFAR1 (0.40) | FFAR1MAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL3631313 | 0.88 | FFAR1 (0.55) | FFAR1MAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL3631695 | 0.86 | FFAR1 (0.38) | FFAR1MAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL3628917 | 0.86 | MAPT (0.35) | MAPTKMT2AALDH1A1MEN1LMNA | |
| SCHEMBL3631605 | 0.85 | FFAR1 (0.35) | FFAR1MAPTKMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786165-B2 | Aminophenylpropanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-31 | — | — | US | disclosed |
| US-7786165-B2 | Aminophenylpropanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-31 | — | — | US | disclosed |
| US-20080269220-A1 | Aminophenylpropanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269220-A1 | Aminophenylpropanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1726580-A1 | AMINOPHENYLPROPANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269220-A1 | Aminophenylpropanoic Acid Derivative | GPR119, GPR55, GPR65 | FFAR1 5/4885MAPT 3293/4885KMT2A 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.